Scientists from the Max Planck Institute for Psycholinguistics and Radboud University in Nijmegen found that genetic variation in the non-coding DNA may lead to language impairments in children and other neurodevelopmental disorders such as schizophrenia, autism, and bipolar disorder.
The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Sanofi’s dupilumab, an investigational treatment for atopic dermatitis (AD), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS).
Heat Biologics has agreed to buy an 80% controlling stake in Pelican Therapeutics, a privately held immuno-oncology company engaged in the development of agonists to TNFRSF25, a differentiated T cell costimulatory receptor.
The US Food and Drug Administration (FDA) has accepted Advaxis’ Investigational New Drug (IND) application for ADXS-NEO, a personalized neoantigen-targeted approach to cancer immunotherapy that is being developed in partnership with Amgen.
A research group from University College London's (UCL) Centre for Rheumatology has been awarded a £3.5m grant from the Medical Research Council (MRC) to advance the development of a novel treatment for anti-phospholipid syndrome (APS) based on Abzena's conjugation technology.
Pharma Two B, a privately held biopharmaceutical firm engaged in the development of treatments for Parkinson’s disease, has closed $30m financing round.
Advaxis has licensed its Lm-based antigen delivery technology to Sellas, under a cancer immunotherapy collaboration that could generate up to $358m for Advaxis.
Versant Ventures has launched Jecure Therapeutics, a biotechnology firm focused on the discovery of novel therapeutics to treat non-alcoholic steatohepatitis (NASH) and liver fibrosis.
X-Chem has expanded its collaboration with Janssen Biotech for the discovery of new drug leads for inflammatory disease treatment.
Eli Lilly and Company has updated label of its once-weekly Trulicity (dulaglutide) to include use in combination with basal insulin for adults with Type 2 diabetes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.